Jefferies Group restated their hold rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a report released on Thursday morning. They currently have a $394.00 price objective on the biopharmaceutical company’s stock.

REGN has been the subject of several other research reports. Cowen and Company restated a hold rating and set a $430.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 5th. Roth Capital restated a buy rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, September 23rd. Vetr lowered shares of Regeneron Pharmaceuticals from a buy rating to a hold rating and set a $422.08 price target for the company. in a research report on Wednesday, July 27th. Piper Jaffray Cos. set a $447.00 price target on shares of Regeneron Pharmaceuticals and gave the company a hold rating in a research report on Thursday, October 13th. Finally, Canaccord Genuity set a $450.00 price target on shares of Regeneron Pharmaceuticals and gave the company a hold rating in a research report on Sunday, November 6th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $468.87.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.16% during mid-day trading on Thursday, reaching $409.24. 228,197 shares of the company’s stock traded hands. The firm has a 50-day moving average of $381.02 and a 200 day moving average of $388.09. The company has a market cap of $42.90 billion, a P/E ratio of 59.71 and a beta of 1.79. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $587.38.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.73 by $0.40. The company earned $1.22 billion during the quarter, compared to the consensus estimate of $1.29 billion. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.47 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals will post $11.73 EPS for the current year.

In other news, Director Arthur F. Ryan sold 2,000 shares of the business’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total transaction of $858,680.00. Following the sale, the director now owns 36,500 shares in the company, valued at approximately $15,670,910. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $450.00, for a total transaction of $956,250.00. Following the sale, the director now owns 15,125 shares in the company, valued at approximately $6,806,250. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in REGN. Fisher Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 620 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 7 shares during the period. Wetherby Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2.3% in the second quarter. Wetherby Asset Management Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18 shares during the period. Waldron LP boosted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the third quarter. Waldron LP now owns 856 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 18 shares during the period. Fagan Associates Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2.5% in the second quarter. Fagan Associates Inc. now owns 820 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 20 shares during the period. Finally, American Money Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.3% in the second quarter. American Money Management LLC now owns 785 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 25 shares during the period. Hedge funds and other institutional investors own 68.58% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.